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Background
The prognostic value of intra-tumoral cytotoxic T cells has
been demonstrated in multiple tumor types. However,
immune infiltrate heterogeneity can lead to potentially sig-
nificant misrepresentations of marker prevalence in rou-
tine histological sections. We examined step sections of
breast and colorectal cancer samples for CD8+ T cell pre-
valence by standard chromogenic immunohistochemistry
to determine marker variability and inform practice of
T cell biomarker assessment in formalin-fixed, paraffin-
embedded (FFPE) tissue samples.
Methods
Serial sections were cut at approximately 25 um intervals
from 13 primary colorectal and 12 breast carcinoma
(8 ductal adenocarcinoma, 4 medullary) FFPE samples
until blocks were exhausted and stained for CD8 using
DAB-based chromogenic immunohistochemistry. Stained
sections were digitally imaged and CD8+ lymphocytes
within defined regions of interest (ROI) including the
tumor and surrounding stroma were enumerated. Using a
linear model/ANOVA framework, statistical analyses of
CD8+ cell count variance between patients as well as
between levels within a patient sample were performed.
Means, medians, and dispersion values of percent CD8
positive cells (CD8 cells/total ROI cells) were calculated.
Similarity of CD8 prevalence between slices of a given
sample was measured by percent of variability accounted
for by slice as a factor in a linear model and an intra-class
correlation coefficient (ICC) ranging from zero (no simi-
larity) to 1 (identical).
Results
The mean and median CD8+ cell percentages varied
between breast ductal adenocarcinoma (mean 11.32%,
median 6.35) and colonic adenocarcinoma samples
(mean 3.91%, median 2.88%) and were highest in medul-
lary breast carcinoma (mean 25.32%, median 18.55%).
However, minimal variation in cytotoxic T cell counts
between levels within any given tumor block was
observed. Percent variability (%) in CD8 counts between
step sections from colonic adenocarcinoma (0.1%),
medullary breast carcinoma (0.1%) and ductal adenocar-
cinoma (0.1%) blocks were minor. ICC calculated for
percent CD8 positive cells between levels of a sample
was 0.99 for both tumor types. Resampling-based meth-
ods show CD8 as reliable marker for classifying patients
as CD8-positive or negative over a range of cut-offs.
Conclusions
Our results show that CD8+ T cell distribution is highly
homogeneous within a standard tissue sample in both
colorectal and breast carcinomas. As such, cytotoxic CD8
T cell prevalence by immunohistochemistry on a single
level can be considered representative of cytotoxic CD8
T cell infiltration for the entire tumor section within the
block. These findings support the technical validity of
biomarker strategies relying on CD8 immunohistochem-
istry in FFPE tumors.
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